^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
FT500
i
Other names: FT-500, FT500, allogeneic iPSC-derived natural killer cell cancer immunotherapy, FT500i
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Fate Therap, University of Minnesota
Drug class:
NK cell stimulant
Related drugs:
over1year
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=37, Completed, Fate Therapeutics | Active, not recruiting --> Completed
Trial completion • Combination therapy • Checkpoint inhibition • Metastases
|
IL2 (Interleukin 2)
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • FT500
over1year
Results of a Phase I trial of FT500, a first-in-class, off-the-shelf, iPSC‑derived NK cell therapy combined with PD-1/PD-L1 checkpoint blockade therapy and IL-2 in patients with advanced solid tumors (SITC 2022)
Methods Treatment consisted of 2 days of outpatient conditioning chemotherapy (cyclophosphamide 300 mg/m 2 and fludarabine 25 mg/m 2 ), followed by two 29-day cycles of 3 once–weekly doses of 300 million FT500 cells/dose with subcutaneous IL-2 (6 MIU), and nivolumab, pembrolizumab, or atezolizumab administered at standard dose and schedule. Ethics Approval This study is being conducted in accordance with the Declaration of Helsinki and was approved by all Institutional Review Boards from each clinical site participating in the study. Specific approval numbers can be provided upon request.
Clinical • P1 data • Checkpoint inhibition
|
IL2 (Interleukin 2)
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • cyclophosphamide • fludarabine IV • FT500
over1year
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=37, Active, not recruiting, Fate Therapeutics | Recruiting --> Active, not recruiting | Trial completion date: Jul 2023 --> Nov 2022 | Trial primary completion date: Mar 2022 --> Oct 2022
Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition • Metastases
|
IL2 (Interleukin 2)
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • FT500
over2years
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=37, Recruiting, Fate Therapeutics | N=76 --> 37 | Trial completion date: Jun 2022 --> Jul 2023
Clinical • Enrollment change • Trial completion date • Combination therapy • Checkpoint inhibition
|
IL2 (Interleukin 2)
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • FT500
Share via
